Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Respiratory chain inactivation links cartilage-mediated growth retardation to mitochondrial diseases.

Holzer T, Probst K, Etich J, Auler M, Georgieva VS, Bluhm B, Frie C, Heilig J, Niehoff A, Nüchel J, Plomann M, Seeger JM, Kashkar H, Baris OR, Wiesner RJ, Brachvogel B.

J Cell Biol. 2019 May 13. pii: jcb.201809056. doi: 10.1083/jcb.201809056. [Epub ahead of print]

PMID:
31085560
2.

BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1β Maturation in Macrophages.

Chauhan D, Bartok E, Gaidt MM, Bock FJ, Herrmann J, Seeger JM, Broz P, Beckmann R, Kashkar H, Tait SWG, Müller R, Hornung V.

Cell Rep. 2018 Nov 27;25(9):2354-2368.e5. doi: 10.1016/j.celrep.2018.10.087.

3.

Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.

Schiffmann LM, Fritsch M, Gebauer F, Günther SD, Stair NR, Seeger JM, Thangarajah F, Dieplinger G, Bludau M, Alakus H, Göbel H, Quaas A, Zander T, Hilberg F, Bruns CJ, Kashkar H, Coutelle O.

Br J Cancer. 2019 Jan;120(1):69-78. doi: 10.1038/s41416-018-0198-3. Epub 2018 Oct 31.

PMID:
30377339
4.

B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.

Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber AN, Trümper L; German International Cancer Genome Consortium Molecular Mechanisms in Malignant Lymphoma by Sequencing Project Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC.

Blood. 2016 Jun 2;127(22):2732-41. doi: 10.1182/blood-2015-11-684183. Epub 2016 Apr 5.

5.

Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.

Förster A, Grotha SP, Seeger JM, Rabenhorst A, Gehring M, Raap U, Létard S, Dubreuil P, Kashkar H, Walczak H, Roers A, Hartmann K.

Allergy. 2015 Jul;70(7):764-74. doi: 10.1111/all.12612. Epub 2015 Apr 16.

PMID:
25833810
6.

IAP antagonization promotes inflammatory destruction of vascular endothelium.

Witt A, Seeger JM, Coutelle O, Zigrino P, Broxtermann P, Andree M, Brinkmann K, Jüngst C, Schauss AC, Schüll S, Wohlleber D, Knolle PA, Krönke M, Mauch C, Kashkar H.

EMBO Rep. 2015 Jun;16(6):719-27. doi: 10.15252/embr.201439616. Epub 2015 Mar 30.

7.

Cytochrome c oxidase deficiency accelerates mitochondrial apoptosis by activating ceramide synthase 6.

Schüll S, Günther SD, Brodesser S, Seeger JM, Tosetti B, Wiegmann K, Pongratz C, Diaz F, Witt A, Andree M, Brinkmann K, Krönke M, Wiesner RJ, Kashkar H.

Cell Death Dis. 2015 Mar 12;6:e1691. doi: 10.1038/cddis.2015.62.

8.

BID-dependent release of mitochondrial SMAC dampens XIAP-mediated immunity against Shigella.

Andree M, Seeger JM, Schüll S, Coutelle O, Wagner-Stippich D, Wiegmann K, Wunderlich CM, Brinkmann K, Broxtermann P, Witt A, Fritsch M, Martinelli P, Bielig H, Lamkemeyer T, Rugarli EI, Kaufmann T, Sterner-Kock A, Wunderlich FT, Villunger A, Martins LM, Krönke M, Kufer TA, Utermöhlen O, Kashkar H.

EMBO J. 2014 Oct 1;33(19):2171-87. doi: 10.15252/embj.201387244. Epub 2014 Jul 23.

9.

Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing.

Coutelle O, Hornig-Do HT, Witt A, Andree M, Schiffmann LM, Piekarek M, Brinkmann K, Seeger JM, Liwschitz M, Miwa S, Hallek M, Krönke M, Trifunovic A, Eming SA, Wiesner RJ, Hacker UT, Kashkar H.

EMBO Mol Med. 2014 May;6(5):624-39. doi: 10.1002/emmm.201303016.

10.

Dimethylfumarate induces apoptosis in human mast cells.

Förster A, Preussner LM, Seeger JM, Rabenhorst A, Kashkar H, Mrowietz U, Hartmann K.

Exp Dermatol. 2013 Nov;22(11):719-24. doi: 10.1111/exd.12247.

PMID:
24112621
11.

Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6Rα signaling.

Gruber S, Straub BK, Ackermann PJ, Wunderlich CM, Mauer J, Seeger JM, Büning H, Heukamp L, Kashkar H, Schirmacher P, Brüning JC, Wunderlich FT.

Cell Rep. 2013 Aug 29;4(4):669-80. doi: 10.1016/j.celrep.2013.07.023. Epub 2013 Aug 15.

12.

Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing.

Brinkmann K, Hombach A, Seeger JM, Wagner-Stippich D, Klubertz D, Krönke M, Abken H, Kashkar H.

Leuk Lymphoma. 2014 Mar;55(3):645-51. doi: 10.3109/10428194.2013.807925. Epub 2013 Jun 26.

PMID:
23697877
13.

Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA.

Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, Schüll S, Andree M, Coutelle O, Yazdanpanah B, Seeger JM, Klubertz D, Drebber U, Hacker UT, Krönke M, Mauch C, Hoppe T, Kashkar H.

Cell Rep. 2013 Mar 28;3(3):881-91. doi: 10.1016/j.celrep.2013.02.014. Epub 2013 Mar 14.

14.

Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils.

Förster A, Falcone FH, Gibbs BF, Preussner LM, Fiebig BS, Altunok H, Seeger JM, Cerny-Reiterer S, Rabenhorst A, Papenfuss K, Valent P, Kashkar H, Hartmann K.

Leuk Lymphoma. 2013 Apr;54(4):835-42. doi: 10.3109/10428194.2012.731600. Epub 2012 Oct 9.

PMID:
22989017
15.

Elevated XIAP expression alone does not confer chemoresistance.

Seeger JM, Brinkmann K, Yazdanpanah B, Haubert D, Pongratz C, Coutelle O, Krönke M, Kashkar H.

Br J Cancer. 2010 Jun 8;102(12):1717-23. doi: 10.1038/sj.bjc.6605704. Epub 2010 May 18.

16.

The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.

Seeger JM, Schmidt P, Brinkmann K, Hombach AA, Coutelle O, Zigrino P, Wagner-Stippich D, Mauch C, Abken H, Krönke M, Kashkar H.

Cancer Res. 2010 Mar 1;70(5):1825-34. doi: 10.1158/0008-5472.CAN-09-3175. Epub 2010 Feb 23.

17.

Interleukin-6 is essential for zwitterionic polysaccharide-mediated abscess formation.

Meemboor S, Mertens J, Flenner E, Groneck L, Zingarelli A, Gamstätter T, Bessler M, Seeger JM, Kashkar H, Odenthal M, Kalka-Moll WM.

Innate Immun. 2010 Oct;16(5):310-21. doi: 10.1177/1753425909346974. Epub 2009 Nov 6.

PMID:
19897529
18.

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK.

Cancer Res. 2009 Apr 15;69(8):3256-61. doi: 10.1158/0008-5472.CAN-08-4055. Epub 2009 Apr 7. Erratum in: Cancer Res. 2015 May 1;75(9):1922.

19.

Midterm outcome after the distal revascularization and interval ligation (DRIL) procedure.

Huber TS, Brown MP, Seeger JM, Lee WA.

J Vasc Surg. 2008 Oct;48(4):926-32; discussion 932-3. doi: 10.1016/j.jvs.2008.05.028. Epub 2008 Jul 18.

20.

Midterm outcomes of femoral arteries after percutaneous endovascular aortic repair using the Preclose technique.

Lee WA, Brown MP, Nelson PR, Huber TS, Seeger JM.

J Vasc Surg. 2008 May;47(5):919-23. doi: 10.1016/j.jvs.2007.12.029. Epub 2008 Mar 6.

21.

Impact of endograft design and product line on the device cost of endovascular aneurysm repair.

Feezor RJ, Huber TS, Berceli SA, Nelson PR, Seeger JM, Lee WA.

J Vasc Surg. 2008 Mar;47(3):499-503. doi: 10.1016/j.jvs.2007.10.051. Erratum in: J Vasc Surg. 2008 Jun;47(6):1381.

22.

Early results after staged hybrid repair of thoracoabdominal aortic aneurysms.

Lee WA, Brown MP, Martin TD, Seeger JM, Huber TS.

J Am Coll Surg. 2007 Sep;205(3):420-31. Epub 2007 Jul 16.

PMID:
17765158
23.

Risk factors for perioperative stroke during thoracic endovascular aortic repairs (TEVAR).

Feezor RJ, Martin TD, Hess PJ, Klodell CT, Beaver TM, Huber TS, Seeger JM, Lee WA.

J Endovasc Ther. 2007 Aug;14(4):568-73.

PMID:
17696634
24.

Genomic and proteomic determinants of lower extremity revascularization failure: rationale and study design.

Nelson PR, O'Malley KA, Feezor RJ, Moldawer LL, Seeger JM.

J Vasc Surg. 2007 Jun;45 Suppl A:A82-91.

25.

Perioperative differences between endovascular repair of thoracic and abdominal aortic diseases.

Feezor RJ, Huber TS, Martin TD, Beaver TM, Hess PJ, Klodell CT, Nelson PR, Berceli SA, Seeger JM, Lee WA.

J Vasc Surg. 2007 Jan;45(1):86-9.

26.

NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.

Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D, Pongratz C, Krönke M.

Blood. 2007 May 1;109(9):3982-8. Epub 2006 Dec 21.

27.

Outcome after hypogastric artery bypass and embolization during endovascular aneurysm repair.

Lee WA, Nelson PR, Berceli SA, Seeger JM, Huber TS.

J Vasc Surg. 2006 Dec;44(6):1162-8; discussion 1168-9.

28.

XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack.

Kashkar H, Seeger JM, Hombach A, Deggerich A, Yazdanpanah B, Utermöhlen O, Heimlich G, Abken H, Krönke M.

Blood. 2006 Nov 15;108(10):3434-40. Epub 2006 Jul 25.

29.

Late type III endoleak from graft erosion of an Excluder stent graft: a case report.

Lee WA, Huber TS, Seeger JM.

J Vasc Surg. 2006 Jul;44(1):183-5.

30.

Outcome after autogenous brachial-axillary translocated superficial femoropopliteal vein hemodialysis access.

Huber TS, Hirneise CM, Lee WA, Flynn TC, Seeger JM.

J Vasc Surg. 2004 Aug;40(2):311-8.

31.

Impact of endovascular repair on early outcomes of ruptured abdominal aortic aneurysms.

Lee WA, Hirneise CM, Tayyarah M, Huber TS, Seeger JM.

J Vasc Surg. 2004 Aug;40(2):211-5.

32.

Withdrawal of article by the FDA after objection from Medtronic.

Cronenwett JL, Seeger JM.

J Vasc Surg. 2004 Aug;40(2):209-10. No abstract available.

33.

Twenty-one cases of aortoenteric fistula: lessons for the general surgeon.

Cendan JC, Thomas JB 4th, Seeger JM.

Am Surg. 2004 Jul;70(7):583-7; discussion 587.

PMID:
15279179
34.

Genomic and proteomic determinants of outcome in patients undergoing thoracoabdominal aortic aneurysm repair.

Feezor RJ, Baker HV, Xiao W, Lee WA, Huber TS, Mindrinos M, Kim RA, Ruiz-Taylor L, Moldawer LL, Davis RW, Seeger JM.

J Immunol. 2004 Jun 1;172(11):7103-9.

35.

Evidence-based data for the hemodialysis access surgeon.

Huber TS, Buhler AG, Seeger JM.

Semin Dial. 2004 May-Jun;17(3):217-23. Review.

PMID:
15144548
36.

Perioperative outcomes after open and endovascular repair of intact abdominal aortic aneurysms in the United States during 2001.

Lee WA, Carter JW, Upchurch G, Seeger JM, Huber TS.

J Vasc Surg. 2004 Mar;39(3):491-6.

PMID:
14981436
37.

Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review.

Huber TS, Carter JW, Carter RL, Seeger JM.

J Vasc Surg. 2003 Nov;38(5):1005-11. Review.

38.

Training standards for physicians performing peripheral angioplasty and other percutaneous peripheral vascular interventions. A statement for health professionals from the Special Writing Group of the Councils on Cardiovascular Radiology, Cardio-Thoracic and Vascular Surgery, and Clinical Cardiology, the American Heart Association.

Levin DC, Becker GJ, Dorros G, Goldstone J, King SB 3rd, Seeger JM, Spies JB, Spittell JA Jr, Wexler L; Councils on Cardiovascular Radiology, Cardiothoracic and Vascular Surgery, and Clinical Cardiology, American Heart Association.

J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S359-61. No abstract available.

PMID:
14514846
39.

Morbidity with retroperitoneal procedures during endovascular abdominal aortic aneurysm repair.

Lee WA, Berceli SA, Huber TS, Ozaki CK, Flynn TC, Seeger JM.

J Vasc Surg. 2003 Sep;38(3):459-63; discussion 464-5.

40.

Leadership in difficult times.

Seeger JM.

J Vasc Surg. 2003 Sep;38(3):413-21. No abstract available.

41.

Role of endogenous interleukin-10 in local and distant organ injury after visceral ischemia-reperfusion.

Welborn MB 3rd, Moldawer LL, Seeger JM, Minter RM, Huber TS.

Shock. 2003 Jul;20(1):35-40.

PMID:
12813366
42.

Approach to patients with "complex" hemodialysis access problems.

Huber TS, Seeger JM.

Semin Dial. 2003 Jan-Feb;16(1):22-9. Review.

PMID:
12535297
43.

Eligibility rates of ruptured and symptomatic AAA for endovascular repair.

Lee WA, Huber TS, Hirneise CM, Berceli SA, Seeger JM.

J Endovasc Ther. 2002 Aug;9(4):436-42.

PMID:
12223003
44.

Prospective validation of an algorithm to maximize native arteriovenous fistulae for chronic hemodialysis access.

Huber TS, Ozaki CK, Flynn TC, Lee WA, Berceli SA, Hirneise CM, Carlton LM, Carter JW, Ross EA, Seeger JM.

J Vasc Surg. 2002 Sep;36(3):452-9.

PMID:
12218966
45.

A technique for combined hypogastric artery bypass and endovascular repair of complex aortoiliac aneurysms.

Lee WA, Berceli SA, Huber TS, Seeger JM.

J Vasc Surg. 2002 Jun;35(6):1289-91.

46.

Durability of antegrade synthetic aortomesenteric bypass for chronic mesenteric ischemia.

Jimenez JG, Huber TS, Ozaki CK, Flynn TC, Berceli SA, Lee WA, Seeger JM.

J Vasc Surg. 2002 Jun;35(6):1078-84. Erratum in: J Vasc Surg 2002 Sep;36(3):548. Jimenez Javier G [corrected to Jimenez Jesus G].

47.

Functional outcome after thoracoabdominal aortic aneurysm repair.

Rectenwald JE, Huber TS, Martin TD, Ozaki CK, Devidas M, Welborn MB, Seeger JM.

J Vasc Surg. 2002 Apr;35(4):640-7.

48.

Interleukin-10 fails to modulate low shear stress-induced neointimal hyperplasia.

Rectenwald JE, Minter RM, Moldawer LL, Abouhamze Z, La Face D, Hutchins E, Huber TS, Seeger JM, Ozaki CK.

J Surg Res. 2002 Feb;102(2):110-8.

PMID:
11796006
49.

Prevention and management of sigmoid and pelvic ischemia associated with aortic surgery.

Welborn MB 3rd, Seeger JM.

Semin Vasc Surg. 2001 Dec;14(4):255-65. Review.

PMID:
11740833
50.

Supplemental Content

Loading ...
Support Center